SRRK enters the post-earnings stretch with a striking shift in how options traders are positioned — running notably more bullish than at any point in the past several months.
The clearest signal this week is the collapse in the put/call ratio. It has dropped to 0.44, well below its 20-day average of 0.55 and near the lower end of its 52-week range of 0.15–1.86. As recently as early-to-mid July, the PCR was running above 0.93 — reflecting elevated demand for downside protection. That has unwound sharply since Scholar Rock reported results on August 6, with the stock posting a one-day gain of more than 10% on the news. The PCR has now held below 0.46 for six consecutive sessions. Options traders have rotated away from defensive hedges and toward call exposure, a meaningful contrast to where positioning was a month ago.
Short interest tells a less straightforward story. At 17.3% of the free float, short positioning remains structurally high — this is not a lightly shorted biotech. That said, the borrow market shows no meaningful stress. Availability is running at roughly 386%, meaning the lending pool holds nearly four shares available to borrow for every share already shorted. Cost to borrow is 0.48%, essentially at the floor it has held all year. Short interest itself barely moved on the week — up just 0.02% — after having stepped down from around 18.7% in mid-July to the current level. The short base has contracted but is not retreating aggressively. Positioning looks contested rather than crowded: shorts are staying put, but the borrow market gives no sign they're under pressure.
The Street is firmly in the bull camp. Citigroup raised its price target to $60 from $58 on August 7, maintaining its Buy rating — a direct response to the earnings print. Wedbush reiterated Outperform with a $58 target last month. Across the analyst universe, targets range from the low-$50s to $70, with a consensus mean of approximately $60 against a current price of $52.92. That implies roughly 13% upside to the average target. The bull case centres on apitegromab's regulatory path: the FDA accepted the BLA resubmission, a second U.S. fill-finish facility reduces manufacturing risk, and a European launch is planned for 2026. Bears flag the binary risk in any clinical-stage name, competition from well-resourced rivals, and the likelihood of further dilutive equity offerings. The ORTEX short score sits at 71 — elevated but broadly stable over the past two weeks, suggesting the market has reached a provisional equilibrium on this name rather than a fresh directional conviction.
Institutional ownership adds some texture. Massachusetts Financial Services entered a new position of 2.6 million shares as of June 30 — the largest single change among the top holders. T. Rowe Price, the largest holder with 5.2% of shares, added modestly. Paradigm Biocapital trimmed its position by over 1.8 million shares in the March quarter, a significant reduction from a specialist biotech investor. The net picture is one of active repositioning rather than quiet accumulation, consistent with a stock that has moved significantly on regulatory and clinical newsflow this year. The 90-day insider net is technically positive at $4 million, but the recent trades on July 1 were all director sells at prices near $53–$55 — routine in size and spread across multiple board members, suggesting routine plan activity rather than a directional signal.
Among correlated peers, RYTM gained 16.5% on the week, while ACAD rose 12.9% — both outperforming or matching SRRK's 11.9% gain, pointing to a broader uplift in rare-disease and specialty biotech names. TYRA fell 16.8% on the week, a reminder of how quickly sentiment can reverse in this space on binary data.
The next scheduled catalyst is the November 12 earnings event. Between now and then, the key variable to monitor is whether the FDA moves toward an approval decision on apitegromab, and whether the recent contraction in short interest extends or stalls as investors assess whether the post-earnings re-rating has fully priced in the regulatory progress.
See the live data behind this article on ORTEX.
Open SRRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
